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Abstract
Macrolide-resistant Streptococcus pneumoniae emerged in Argentina in 1995, representing 
26% of invasive infection isolates in children under 5 years old. The objectives of this 
study were to describe the prevalence of ermB and mefA genes in macrolide-resistant 
S. pneumoniae isolates from acute otitis media (AOM) and to determine their genetic 
relatedness. Between May 2009 and August 2010, 126 S. pneumoniae isolates from 324 
otherwise healthy children with a À rst episode of AOM were included. Twenty six of these 
isolates (20.6%) were resistant to erythromycin. Most frequent serotypes were: 14 
(46.2%), 6A (23.1%), 19F (7.7%) and 9V (7.7%). Twenty (76.9%) carried the mefA gene, 5 
(19.2%) have the ermB gene, and 1 (3.9%) both ermB + mefA. Ten clonal types were 
identiÀ ed, mostly related to Sweden15A-25/ST782 (SLV63), CloneB6A/ST473 and England14-9/
ST9. This is the À rst study assessing the mechanisms of macrolide resistance in 
pneumococci isolates from pediatric AOM in Argentina and their genetic relatedness. 
© 2013 Asociación Argentina de Microbiología. Published by Elsevier España, S.L. All 
rights reserved.
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Acute otitis media (AOM) is by far the most common disease 
caused by Streptococcus pneumoniae and one of the most 
frequent diagnoses in children under 2 years old. One out of 
every three children has at least one episode of AOM during 
the À rst three years of life1. 
Over the last years, resistance to penicillin in 
S. pneumoniae has increased in Latin America and 
worldwide10,11. Consequently, macrolides were used as 
initial empiric therapy for community-acquired respiratory 
tract infections11. Unfortunately, resistance to macrolides 
in S. pneumoniae has also evolved rapidly and in many 
countries the rate of S. pneumoniae resistant to macrolides 
exceeded the level of resistance to penicillin2,8. Results 
from a global international surveillance project (PROTEKT, 
1993-2003) showed an increase in macrolide resistance 
from 31% in 1999 to 36.3% in 200311. Macrolide resistance in 
S. pneumoniae causing infectious diseases in pediatric 
patients emerged in Argentina in 1995 and À rstly increased 
to 1.4% between 1995-1997 and later to 6% in the period 
1998-20016. Nowadays, according to the Argentinian SIREVA 
II surveillance data, macrolide resistance reached 30.2% in 
201110. Four different mechanisms of resistance to 
macrolides have been described: antibiotic efÁ ux, mediated 
by mefA gene; target-site modiÀ cation by methylation of 
23S rRNA due to erm genes; mutations in riboproteins L4 or 
L22 and mutations in domain II or V of 23S rRNA. The mefA 
gene, displaying an M-phenotype, has been associated with 
resistance to 14- and 15-membered macrolides. The ermB 
gene is known to confer cross-resistance to macrolides, 
lincosamides and streptogramins B, yielding the MLSB-
phenotype9. 
The objectives of the present study were to determine 
the frequency of macrolide-resistant S. pneumoniae isolates 
from AOM, the prevalence of ermB (ribosomal methylase) 
and mefA (efÁ ux pump) genes and to determine their 
genetic relatedness.
Between May 2009 and August 2010, 324 immunocompetent 
children under 120 months (median age: 8 months) with a 
À rst episode of AOM with purulent exudates in the middle 
ear were included in this study. Immunocompromised 
patients and those with chronic otitis media were excluded. 
All middle ear specimens obtained through tympanocentesis 
were cultured under standard conditions7. One hundred and 
thirty three pneumococci were isolated from 324 children 
suffering from AOM (41%), but 126 were available for this 
study.
Pneumococcal strains were serotyped by the Neufeld 
Quellung reaction using antiserum from the Statens Serum 
Institut, Copenhagen, Denmark.
Minimal inhibitory concentrations (MIC) were determined 
by the agar dilution method using Mueller Hinton agar 
(Difco, BD, USA) supplemented with 5% sheep blood and 
incubated overnight at 35 °C. MIC values of penicillin, 
amoxicillin, cefotaxime, erythromycin and clindamycin 
were interpreted according to Clinical and Laboratory 
Standards Institute recommendations. Susceptibility to 
chloramphenicol, tetracycline, oÁ oxacin, vancomycin and 
trimethoprim-sulfamethoxazole was tested by the disk 
diffusion method according to the CLSI guidelines. 
Phenotypic characterization of macrolide resistance was 
performed by the double-disk diffusion method (D test), 
using disks of erythromycin (15 μg) and clindamycin (2 μg) 
to discriminate isolates expressing the M- and MLSB-
phenotype (inducible or constitutive). MICs were interpreted 
according to the CLSI guidelines5. 
PCR assays for detection of mefA and ermB genes and 
pulse-À eld gel electrophoresis (PFGE) were performed as 
previously described (6). PFGE patterns were categorized 
using the Tenover criteria14 and compared to international 
clones (http://www.sph.emory.edu/PMEN/). Multilocus 
sequence typing (MLST) was carried out as previously 
described, with À ve selected strains of each dominant PFGE 
pattern and those associated with international clones 
(www.mlst.net/). 
Twenty six of the 126 available pneumococci (20.6%) 
were classiÀ ed as erythromycin-resistant and were further 
studied. Although macrolide resistance in our country has 
been increasing steadily since 199510, these resistance 
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Resumen
Streptococcus pneumoniae resistente a macrólidos emergió en la Argentina en 1995 y re-
presenta el 26 % de los aislamientos de infecciones invasivas en niños menores de 5 años. 
El objetivo de este trabajo fue describir la prevalencia de ermB y mefA en neumococos 
resistentes a macrólidos aislados de niños con otitis media aguda (OMA) y determinar 
su relación genética. En 15 meses se incluyeron 126 neumococos aislados de 324 niños 
previamente sanos, con un primer episodio de OMA. Veintiseis (20,6 %) eran resisten-
tes a eritromicina. Los serotipos más frecuentes fueron los siguientes: 14 (46,2 %), 6A 
(23,1 %), 19F (7,7 %) y 9V (7,7 %). Veinte eran portadores del gen mefA, 5 del gen ermB 
y el restante portaba ambos genes. Se identiÀ caron 10 tipos clonales, la mayoría rela-
cionados con los clones Sweden15A-25/ST782 (SLV63), CloneB6A/ST473 y England14-9/ST9. 
Este es el primer estudio en determinar los mecanismos de resistencia a macrólidos en 
neumococos aislados de OMA en la Argentina y en describrir su relación genética. 
© 2013 Asociación Argentina de Microbiología. Publicado por Elsevier España, S.L. Todos 
los derechos reservados.
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levels do not exceed erythromycin resistance from invasive 
infections in other countries4. Most frequent serotypes 
among macrolide-resistant pneumococci from AOM were (n; 
%): 14 (12; 46.3) and 6A (6; 23.1); followed by 19F (2; 7.7), 
9V (2; 7.7), 6B (1; 3.8), 19A (1; 3.8), 33F (1; 3.8) and non-
typeable (1; 3.8) compared with 14 and 6B, found in a 
previous study of invasive infections6. Almost in coincidence 
with our results, in Bedouin and Jewish children with AOM, 
predominant serotypes with macrolide resistance were: 6A, 
6B, 14, 19A and 19F13 and in Bulgarian children, the 
predominant serotypes were: 6B, 19A and 19F12. MIC range, 
MIC50 and MIC90 for penicillin, amoxicillin, cefotaxime, 
erythromycin and clindamycin of the 26 isolates are shown 
in Wable 1. In 65.4% of cases, erythromycin resistance was 
associated with penicillin MICs between 0.12 and 1 μg/ml. 
Breakpoints for penicillin were those recommended for oral 
penicillin V5. We have to emphasize that applying the 
current breakpoints of CLSI, all isolates were susceptible to 
amoxicillin, which is the antibiotic recommended for the 
empirical treatment of AOM in our country. All isolates were 
susceptible to cefotaxime (MIC ≤ 1 μg/ml), and also to 
chloramphenicol, oÁ oxacin and vancomycin when tested by 
the disk diffusion method, using the breakpoints 
recommended by the CLSI5.
Resistance to erythromycin was recorded in 26 (20.6%) 
isolates of S. pneumoniae from AOM, mainly due to the 
presence of the mefA gene. Resistance to tetracycline and 
trimethoprim-sulfamethoxazole was observed in 13 (50%) 
and in 15 (57.7%) macrolide-resistant isolates, respectively. 
Twenty of the 26 macrolide resistant isolates (76.9%) 
expressed the M-phenotype and were positive for the mefA 
gene, while 6 (23.1%) expressed the constitutive MLSB-
phenotype. Five of them were positive for the ermB gene 
and one was positive for both genes (Wable 1). As has been 
previously described, isolates displaying the MLSB-phenotype 
showed higher MICs of erythromycin and clindamycin than 
those with the M-phenotype. All S. pneumoniae serotype 
14 isolates harbored the mefA gene (11/12 expressed the 
M-phenotype and 1/12 expressed the MLSB-phenotype due 
to the presence of both mefA and ermB genes). All serotype 
6A isolates harbored the mefA gene and expressed the 
M-phenotype. Our results are consistent with previous 
Argentinian data of macrolide-resistant S. pneumoniae 
isolated between 1993 and 20016. However, in European 
countries, macrolide-resistant S. pneumoniae strains are 
predominantly ermB positive12 and in South Korea 
dissemination of macrolide-resistant S. pneumoniae was 
due to isolates containing the ermB gene alone or 
concomitantly with the mefA gene15. None of the macrolide-
resistant isolates was found to be mefA and ermB negative. 
Other macrolide resistance mechanisms, such as mutations 
in the 23S rRNA or alterations in ribosomal proteins L4 and 
L22 have not been investigated. 
Ten (10) clonal types (A to J) were deÀ ned by the SmaI-
PFGE pattern. (Iig.1). Seventeen isolates were grouped 
into three clones: clone A n:7, clone B n:6, and clone C n:4. 
The PFGE pattern of clones A and C were related to 
Sweden15A-25 and England14-9 international clones deÀ ned 
in PMEN while clone B6A was not related to any international 
clone. The remaining nine isolates were grouped into seven 
clones, of which only two were related to international 
clones: Spain9V-3 and Poland6B-20 (Wable 2). In the study of 
Corso et al. referring to invasive infections, the emergency 
of erythromycin-resistant S. pneumoniae was principally 
Table 1 Minimal inhibitory concentration and 
correlation among phenotypes and genotypes of 
macrolide-resistant Streptococcus pneumoniae
MIC range 
(μg/ml)
MIC50 
(μg/ml)
MIC90 
(μg/ml)
Total (26)
M phenotype (20)
mefA (20) PEN ≤0.016-0.25 0.12 0.125
AMX ≤0.016-0.25 0.06 0.125
CTX ≤0.016-0.25 0.06 0.25
ERY 4-64 8 64
CLI 0.12-0.25 0.25 0.25
MLSB phenotype (6)
ermB (5)
ermB + mefA (1) PEN 0.016-0.25 NA NA
AMX ≤0.016-0.125 NA NA
CTX 0.016-0.125 NA NA
ERY 1024->1024 NA NA
CLI 512 NA NA
PEN, penicillin; AMX, amoxicillin; CTX, cefotaxime; ERY, 
erythromycin; CLI, clindamycin; NA, not applicable.
Table 2 Comparison of macrolide-resistant isolates 
with international clones
Clone 
(PFGE)
International 
clone by 
PFGE
ST No. of 
isolates 
(%)
Serotype Genotype
A Sweden15A-25 782 7 (27) 14 mefA (n= 6)
mefA+ermB 
(n=1)
B 473 6 (23.1) 6A mefA
C England14-9 9 4 (15.5) 14 mefA
D Spain 9V-3 162 2 (7.7) 9V mefA
E 2 (7.7) 19F ermB
F 1 (3.8) 33F ermB
G 1 (3.8) NT ermB
H 1 (3.8) 19A mefA
I Poland6B-20 315 1 (3.8) 6B ermB
J 1 (3.8) 14 mefA
NT, non-typeable.
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due to the England14-9, Poland6B-20 and Spain9V-3 
international clones 6, while in the present study both the 
Sweden15A-25 and CloneB6A clones were the major ones 
(Wable 2). This could be the consequence of differences in 
spreading trends of clonal types producing AOM with respect 
to those producing invasive infections.
MLST was performed on clones which showed higher 
frequencies and on those that were associated with some 
international clones. All the isolates belonging to the 
Sweden15A-25 clone were ST782 (SLV63) and clustered to 
CC63. CloneB6A was ST473 and clone England14-9 was 
ST9. Clone Spain9V-3 was ST162, a single locus variant of 
ST156. Clone Poland6B-20 was ST315 (Wable 2). Although 
PFGE patterns were identical to the Sweden15A-25 and 
Spain9V-3 clones, when we performed MLST, we noted that 
our isolates had different ST but belonged to highly related 
clonal complexes.
Sweden15A-25 (CC63) is a worldwide disseminated clone 
usually showing capsular switching (serotype 19F or 19A). 
This clone has been described in Spain as a cause of 
meningitis and among multidrug- and ciproÁ oxacin-resistant 
strains with different serotypes (14, 19A, 19F, and 23F). In 
previous European studies4, the Sweden15A-25 clone was the 
most frequently found clone among erythromycin-resistant 
pneumococci (www.mlst.net). The MLST database includes 
several ST63 isolates recovered from AOM in France. 
However, this database does not contain ST782 isolates 
from AOM. In the present study, the Sweden15A-25 clone was 
also the most frequently found clone expressing serotype 
14, probably due to a previous capsular switching event.
Alonso et al. studied pneumococcal isolates causing AOM 
in a region of Northern Spain between 1999 and 2010. The 
authors detected that clones ST63 and ST156 were only 
occasionally present in their region, the last one associated 
with ERY-susceptible isolates1. Bowers et al. reported the 
dominance of multidrug-resistant CC271 clones in 
macrolide-resistant pneumococci in Arizona, principally 
due to the dual genotype (mefE/ermB)3. Among the mef 
positive isolates, they found two belonging to the ST156 
clone, one of them showing serotype 9V, similar to clone D 
isolates found in our study, and one isolate belonging to the 
ST162 clone. Among the ermB positive isolates, they found 
eight ST63 and two ST315, with serotype 6B, similar to 
clone I.
This study was carried out before the introduction of the 
PCV13 vaccine in our immunization schedule in 2012; 
therefore, it deserves to be repeated later, to evaluate the 
vaccine effectiveness and the possible spread of new 
S. pneumoniae clones in AOM.
Although macrolides or lincosamides are not À rst-line 
antibiotics for the treatment of AOM, the knowledge about 
the prevalence of different macrolide-resistant mechanisms 
allowed us to assess and eventually predict their 
dissemination among pneumococci. 
Although in our country we have data on the evolution of 
macrolide-resistant S. pneumoniae since 1995 from invasive 
infections and AOM 6, this is the À rst study assessing the 
mechanisms of macrolide resistance and genetic relatedness 
of S. pneumoniae isolated from pediatric patients suffering 
from AOM in Argentina.
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Figure 1 Pulse-À eld gel electrophoresis proÀ les of 25 erythromycin-resistant isolates and representative strains of international 
disseminated clones. Ŋ ladder, molecular size marker; R1, England14-9; R2, Poland6B-20; R3, Spain9V-3; R4, Sweden15A-25; R5, 
reference strain R6.
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